[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results

@article{Pasqualetti201618FCholinePA,
  title={[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results},
  author={F. Pasqualetti and M. Panichi and A. Sainato and F. Matteucci and L. Galli and P. Cocuzza and P. Ferrazza and G. Coraggio and G. Pasqualetti and L. Derosa and M. Sollini and L. Mannelli and S. Ortori and F. Monzani and S. Ricci and C. Greco and M. Fabrini and P. Erba},
  journal={Radiation Oncology (London, England)},
  year={2016},
  volume={11}
}
BackgroundA new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [18F]Choline ([18F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients… Expand
Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer
TLDR
Treating a castration-resistant PCa patient with 18F-choline PET/CT-guided SBRT could achieve sufficient prostate-specific antigen (PSA) control, but a clear benefit of this procedure in terms of significant endpoints is yet to be demonstrated. Expand
Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone‐Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT
TLDR
SBRT can safely and effectively be used to postpone ADT in appropriately selected patients with oligometastatic recurrence of PC and time between diagnosis of the metastasis until progression of disease during ADT use (castration resistance) was longer for the SBRT‐treated patients. Expand
Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.
TLDR
The number of choline-avid metastases was a significant prognostic factor for progression after [18F]-fluormethylcholine PET/CT-guided SBRT for recurrent oligometastatic prostate cancer, and there seemed to be a trend in risk of progression for patients with large MATVs. Expand
68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
TLDR
For patients with OMPC, SBRT might be used as an alternative to ADT and its side effects can be deferred, and low PSA levels and longer TTM predict elongated TFFS. Expand
Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer
TLDR
FCH PET-positive node-targeted s-EFRT is feasible with low rates of toxicity and longer TTF, suggesting that oligorecurrent nodal disease diagnosed on FCH PET is unlikely. Expand
Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer
TLDR
11C-choline PET/CT and the correspondent local treatments may play an important role in the treatment sequence of CRPC in selected patients. Expand
Single-Center Experience of Focal Thermo-Ablative Therapy After Pelvic Radiotherapy for In-Field Prostate Cancer Oligo-Recurrence
TLDR
In PCa patients showing in-field oligo-recurrence after pelvic radiotherapy, focal ablative treatment is a feasible option, possibly delaying a systemic treatment initiation or modification. Expand
Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml
TLDR
In patients with early recurrence of PC, 18F-FCH PET/CT is able to detect OMD in 40% of cases, which has an important impact on the detection of PC recurrent lesions that could be treated by local therapy to achieve long‐term survival or cure. Expand
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study
TLDR
Overall, BRFS was dependent on patterns of metastatic disease, and MDR of PSMA PET-positive oligo-metastases can be offered considering that about one-third of the patients progressed within a median follow-up of 16 months. Expand
Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
TLDR
SBRT seems to be promising in lymph node oligorecurrent prostate cancer, although there is a weak level of evidence to support such investigational treatment, which is currently based on retrospective studies of single-institution or pooled experiences. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
TLDR
Repeated salvage SBRT is feasible, well tolerated and defers palliative ADT with a median of 38 months in patients with limited bone or lymph node PCa metastases. Expand
18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.
TLDR
A positive 18F-FEC PET/CT result correctly predicted the presence of LNM in the majority of PCa patients with biochemical failure after radical prostatectomy but did not allow for localization of all metastatic lymph nodes and therefore was not adequately accurate for the precise estimation of extent of nodal recurrence in these patients. Expand
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
TLDR
Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation therapy with 2 years without grade III toxicity. Expand
Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
TLDR
C-choline PET/CT showed a better sensitivity than BS in patients with biochemical relapse after RP in prostate cancer patients, and detected unknown bone lesions in 18/123 patients. Expand
[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.
TLDR
Positron emission tomography/computerized tomography detected increased [11C]choline uptake, suggesting recurrent disease in 11% of patients with prostate cancer, increasing prostate specific antigen after radical prostatectomy and no evidence of disease on conventional imaging. Expand
Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
TLDR
Salvage LND is feasible in patients with BCR after RP and nodal pathologic uptake at [11C]choline PET/CT scan and postoperative independent predictors of clinical recurrence (CR). Expand
Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases.
TLDR
High-dose SD-IGRT is a noninvasive procedure resulting in high probability of local tumor control and may be effectively used to locally control metastatic deposits regardless of histology and target organ, provided sufficiently high doses of radiation are delivered. Expand
Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
TLDR
MDT is a promising approach for oligometastatic PCa recurrence, but the low level of evidence generated by small case series does not allow extrapolation to a standard of care, and requires validation in randomised controlled trials. Expand
Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma.
TLDR
High single-dose, image-guided, intensity-modulated radiotherapy is a noninvasive procedure resulting in high probability of local tumor control for metastatic renal cell cancer generally considered radioresistant according to the classic radiobiologic ranking. Expand
Stereotactic body radiotherapy for oligometastases.
The management of metastatic solid tumours has historically focused on systemic treatment given with palliative intent. However, radical surgical treatment of oligometastases is now common practiceExpand
...
1
2
3
...